Q-omics provides the consensus-scored RN7SKP261 profile across patient tissues and cancer cell-line models. RN7SKP261 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, RN7SKP261 is differentially expressed in 3, with the highest sampling consensus in BLCA. Additionally, RN7SKP261 RNA expression shows 6,606 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUAD, BLCA, and STAD as cancer lineages where RN7SKP261 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SKP261 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SKP261 survival associations across molecular data types. RN7SKP261 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SKP261 RNA expression–survival associations across cancer types. High RN7SKP261 expression shows unfavorable associations in LUAD, THYM, ESCA, MESO, ACC and CESC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify LUAD as the clearest survival context for RN7SKP261 RNA expression.
This table summarizes RN7SKP261 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SKP261. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SKP261 shows lower tumor expression in LUAD and LUSC and higher tumor expression in BLCA. The BLCA box plot shows higher RN7SKP261 RNA expression in tumor versus normal tissue (log2 FC = +0.110, t-test p = .034).
This table shows molecular features associated with RN7SKP261 in patient tissues and cancer cell lines. In patient samples, RN7SKP261 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
